Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05656027 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia
A Phase 3 study, sponsored by LENZ Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 469
- Enrollment target
NCT05656027 is a Phase 3 study that has completed, run by LENZ Therapeutics. The registered enrollment target is 469 participants.
The verdict
NCT05656027, a Phase 3 study, has completed, sponsored by LENZ Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 469 participants
- Enrollment target
Study Summary
Phase 3 study to evaluate the safety and effectiveness of LNZ100 \& LNZ101 for the treatment of Presbyopia.
Interventions
- DRUG Aceclidine+Brimonidine combination ophthalmic solution
- DRUG Aceclidine ophthalmic solution
- DRUG Brimonidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 469 participants |
| Start Date | 2022-12-19 |
| Est. Completion | 2024-01-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05656027
The ClinicalTrials.gov registry entry for NCT05656027 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 469 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LENZ Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Aceclidine+Brimonidine combination ophthalmic solution is the first listed.
NCT05656027 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05656027 about?
NCT05656027 is a clinical study titled "Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia". Phase 3 study to evaluate the safety and effectiveness of LNZ100 \& LNZ101 for the treatment of Presbyopia.
What is the current status of trial NCT05656027?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 469 participants. The study started on 2022-12-19. Estimated completion is 2024-01-25.
What interventions are being tested in trial NCT05656027?
The interventions under investigation include: Aceclidine+Brimonidine combination ophthalmic solution (DRUG), Aceclidine ophthalmic solution (DRUG), Brimonidine (DRUG).
Who is sponsoring clinical trial NCT05656027?
This trial is sponsored by LENZ Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.